Aurobindo Pharma falls 7% on receiving warning letter from USFDA for Srikakulam facility
Updated : June 21, 2019 11:29 AM IST
The stock fell as much as 7.6 percent to Rs 578.75 per share on the BSE in the opening trade.
The company received a warning letter from the US FDA for Srikakulam facility after the February inspection.
The stock has fallen 12 percent in the last one month and 20 percent in 2019.